Psyadon Pharmaceuticals

Psyadon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for rare and serious neurological disorders, most notably Tourette syndrome. The company has conducted clinical trials for ecopipam, a selective dopamine D1/D5 receptor antagonist being investigated as a potential treatment for Tourette syndrome in both pediatric and adult populations. Based in Germantown, Maryland, Psyadon operates as a small, focused drug development organization targeting underserved CNS conditions where current treatment options remain limited.